In CheckMate-069, ipilimumab in combination with nivolumab in BRAF wildtype untreated melanoma, as well as unresectable/metastatic melanoma patients, provided PFS advantage compared to ipilimumab alone (median PFS: not reached vs. 4.4 months; HR: 0.40; 95% CI: 0.23–0.68; p < 0.001), granting the combination FDA approval for use in BRAF V600 wild-type tumors [98]. This evidence concerns the gene BRAF and metastatic melanoma.